Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.
about
A camelid anti-PrP antibody abrogates PrP replication in prion-permissive neuroblastoma cell linesEffective gene therapy in a mouse model of prion diseasesCrystal structure of human prion protein bound to a therapeutic antibodyThe crystal structure of an octapeptide repeat of the Prion protein in complex with a Fab fragment of the POM2 antibodyLive imaging of prions reveals nascent PrPSc in cell-surface, raft-associated amyloid strings and websClearance and prevention of prion infection in cell culture by anti-PrP antibodies.Mapping of possible prion protein self-interaction domains using peptide arraysInfluence of Mabs on PrP(Sc) formation using in vitro and cell-free systemsPrion protein-specific antibodies-development, modes of action and therapeutics applicationSelective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation.Characterization of four new monoclonal antibodies against the distal N-terminal region of PrP(c).Abrogation of complex glycosylation by swainsonine results in strain- and cell-specific inhibition of prion replication.Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury.Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells.Polythiophenes inhibit prion propagation by stabilizing prion protein (PrP) aggregates.Progress in prion vaccines and immunotherapies.Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivoPrion protein-specific antibodies for therapeutic intervention of transmissible spongiform encephalopathies.A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies.Detection and control of prion diseases in food animals.Therapeutic approaches for prion disorders.Gene therapy for misfolding protein diseases of the central nervous system.Toxic effects of intracerebral PrP antibody administration during the course of BSE infection in mice.Prion protein scrapie and the normal cellular prion proteinAnti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivoThe consequences of pathogenic mutations to the human prion protein.Antibody-based immunotherapeutic attempts in experimental animal models of prion diseases.Immunotherapy for prion diseases: opportunities and obstacles.Progress in the development of therapeutic antibodies targeting prion proteins and beta-amyloid peptides.Prion protein self-interaction in prion disease therapy approaches.Safety, specificity and immunogenicity of a PrP(Sc)-specific prion vaccine based on the YYR disease specific epitope.The potential of mesenchymal stem cell in prion research.The N Terminus of the Prion Protein Mediates Functional Interactions with the Neuronal Cell Adhesion Molecule (NCAM) Fibronectin Domain.Inhibition of PrPSc formation by lentiviral gene transfer of PrP containing dominant negative mutations.Induction of PrPSc-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease.Therapeutic effect of peripheral administration of an anti-prion protein antibody on mice infected with prions.
P2860
Q21562652-C6F935E8-5051-4D39-9B74-1DE51B3EFA28Q27300832-57D90C91-1E91-43B1-ACCB-A60D93073A46Q27653698-DF1BD86A-BAF8-491F-89D6-5C99B43B525EQ27677854-130D59F7-EDE2-4922-B8CE-1D4B88FBB6E0Q30570683-8154E982-B70B-42B1-8B44-15254E5E7214Q33248701-F33A3E0F-8180-4572-90C6-77C7391C653BQ33281952-779DFD91-40B5-453B-B896-8BFF253FDD9EQ34358708-8DB272D3-CD98-4300-BE49-D6FF8A1D0B9FQ34423386-B2828918-A554-42AD-B8B3-01A65D5D937BQ34633462-04F4F976-B565-4EB6-BE65-8875611904F1Q35205070-FBDB7514-87A7-466C-9565-4B643367B2D8Q35562607-75962EFE-2287-4D11-BDF5-7876B45BD1FFQ35674443-CF8841F2-3FB3-435B-9059-F0E2F7D99058Q35844090-EBAA0284-6CB8-4E7C-897C-CEED8A05F969Q36003595-2353242A-0FE2-4DB6-A117-3D9B259793DEQ36040834-77037B10-F409-419B-9871-463CA7357184Q36271462-C2957A8E-32F4-48E0-A207-9B8563E0F440Q36407253-E2D3B3C5-3C7B-43FC-9E1B-A7C75FDACF48Q36503630-D90A7FD0-27D2-4B8C-939B-BB5A029BDF6EQ36780126-0F908C97-E697-44A5-B2C0-503B96FC97AFQ36857700-53F7A82B-4E79-4EAA-9DA2-F87726F4E41DQ36901944-378D661A-DF87-496B-9518-E87656FB2548Q36983203-30F202BD-DF59-4FF9-88A0-DE1EEF95988CQ37080697-ABDF2B5E-0808-44B7-B820-D4ACF1FB4AB5Q37167885-4E051C20-CA3D-4914-8BA0-4AC32687B62AQ37267798-D7AD9297-9970-4E21-A0F8-0A98F7DE80E6Q37285520-998142A9-C56D-4969-B78C-B79A763EE639Q37514313-F66ABB59-03AC-4DB0-8412-B09E4255EF44Q37773260-C95F20C0-8333-47E8-A040-C2D28E1930F9Q37785871-BDE42658-E29C-43A7-97EE-763C3F0AC1FDQ37949697-CD497F21-FF1F-4240-ABA5-2EE7F5C59D92Q38186543-EE7DE507-6AEF-4804-B68D-E66909B7AEDCQ38213991-70811C54-8506-42DB-8295-E4DFAC953A71Q39480254-347241AF-E596-4C7D-BC4F-43553B3BE219Q39692874-C386A823-EDC4-483A-B63E-DAB69FA36E66Q41992326-28BF0BA5-A3BA-4680-83A7-F749A33CFB6CQ51068268-6638E8C5-E91F-44FA-8737-055363803180
P2860
Anti-PrP antibodies block PrPSc replication in prion-infected cell cultures by accelerating PrPC degradation.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Anti-PrP antibodies block PrPS ...... accelerating PrPC degradation.
@en
Anti-PrP antibodies block PrPS ...... accelerating PrPC degradation.
@nl
type
label
Anti-PrP antibodies block PrPS ...... accelerating PrPC degradation.
@en
Anti-PrP antibodies block PrPS ...... accelerating PrPC degradation.
@nl
prefLabel
Anti-PrP antibodies block PrPS ...... accelerating PrPC degradation.
@en
Anti-PrP antibodies block PrPS ...... accelerating PrPC degradation.
@nl
P2093
P2860
P50
P1476
Anti-PrP antibodies block PrPS ...... accelerating PrPC degradation
@en
P2093
Chantal Mourton-Gilles
Jacques Grassi
Sylvain Lehmann
Yveline Frobert
P2860
P304
P356
10.1111/J.1471-4159.2004.02356.X
P407
P577
2004-04-01T00:00:00Z